Oritavancin: A Long-Half-Life Lipoglycopeptide

Clinical Infectious Diseases

Volumn 61, Issue 4, 2015, Pages 627-632

  Saravolatz, Louis D ^a,b   Stein, Gary E ^a,b  

^a ST JOHN HOSPITAL AND MEDICAL CENTER   (United States)

^b MICHIGAN STATE UNIVERSITY   (United States)

Author keywords

antibacterial agents; MRSA; oritavancin; Staphylococcus aureus

Indexed keywords

LIVER ENZYME; ORITAVANCIN; ANTIINFECTIVE AGENT; ENZYME; GLYCOPEPTIDE;

ANTIMICROBIAL ACTIVITY; AREA UNDER THE CURVE; BACTERIAL SKIN DISEASE; DRUG CLEARANCE; DRUG EFFICACY; DRUG ELIMINATION; DRUG FORMULARY; DRUG HALF LIFE; DRUG MECHANISM; DRUG SAFETY; ELIMINATION HALF-LIFE; FOLLOW UP; HUMAN; HYPERTRANSAMINASEMIA; MAXIMUM PLASMA CONCENTRATION; MULTICENTER STUDY (TOPIC); NONHUMAN; OSTEOMYELITIS; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SKIN STRUCTURE; BLOOD; CHEMICALLY INDUCED; CLINICAL TRIAL (TOPIC); DRUG EFFECTS; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; ENZYMOLOGY; GRAM-POSITIVE BACTERIAL INFECTIONS; HALF LIFE TIME; INTRAVENOUS DRUG ADMINISTRATION; LIVER; PATHOLOGY; SKIN DISEASES, BACTERIAL; SOFT TISSUE INFECTIONS;

ADMINISTRATION, INTRAVENOUS; ANTI-BACTERIAL AGENTS; CLINICAL TRIALS AS TOPIC; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; ENZYMES; GLYCOPEPTIDES; GRAM-POSITIVE BACTERIAL INFECTIONS; HALF-LIFE; HUMANS; LIVER; OSTEOMYELITIS; SKIN DISEASES, BACTERIAL; SOFT TISSUE INFECTIONS;

EID: 84938559939     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/civ311     Document Type: Review

References (39)

1. Kirst HA, Thompson DG, Nicas TI. Historical yearly usage of vancomycin. Antimicrob Agents Chemother 1998; 42:1303-4.
2. Pakyz AL, MacDougall C, Oinenen M, Polk RE. Trends in antibacterial use in US academic health centers. Arch Intern Med 2008; 168: 2254-60.
3. Sakoulas G, Moise-Broder PA, Schentag J, et al. Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia. J Clin Microbiol 2004; 42:2398-402.
4. Twele L, Moyen E, Zhang K, Dalton B, Church D, Conly J. Methicillinresistant Staphylococcus aureus endocarditis and de novo development of daptomycin resistance during therapy. Can J Infect Dis Med Microbiol 2010; 21:89-93.
5. Tsiodras S, Gold HS, Sakoulas G, et al. Linezolid resistance in a clinical isolate of Staphylococcus aureus. Lancet 2001; 358:207-8.
6. Zhanel GG, Schweizer F, Karlowsky JA. Oritavancin: mechanism of action. Clin Infect Dis 2012; 54(suppl 3):S214-9.
7. Guskey MT, Tsuji BT. Comparative review of the lipoglycopeptides oritavancin, dalbavancin, and telavancin. Pharmacotherapy 2010; 30:80-94.
8. Belley A, McKay GA, Arhin FF, et al. Oritavancin disrupts membrane integrity of Staphylococcus aureus and vancomycin-resistant enterococci to effect rapid bacterial killing. Antimicrob Agents Chemother 2010; 54:5369-71.
9. Belley A, Neesham-Grenon E, McKay G, et al. Oritavancin kills stationary-phase and biofilm Staphylococcus aureus cells in vitro. Antimicrob Agents Chemother 2009; 53:918-25.
10. Baquir B, Lemaire S, Van Bambeke F, et al. Macrophage killing of bacterial and fungal pathogens is not inhibited by intense intracellular accumulation of the lipoglycopeptide antibiotic oritavancin. Clin Infect Dis 2012; 54(suppl 3):S229-32.
11. Mendes RE, Farrell DJ, Sader HS, Jones RN. Oritavancin microbiologic features and activity results from the surveillance program in the United States. Clin Infect Dis 2012; 54(suppl 3):S203-13.
12. Mendes RE, Farrell DJ, Sader HS, Flamm RK, Jone RN. Baseline activity of telavancin against gram-positive clinical isolates responsible for documented infections in U.S. hospitals (2011-2012) as determined by the revised susceptibility testing method. Antimicrob Agents and Chemother 2015; 59:702-6.
13. Billeter M, Zervos MJ, Chen AY, Dalovisio JR, Kurukularatne C. Dalbavancin: a novel once-weekly lipoglycopeptide antibiotic. Clin Infect Dis 2008; 46:577-83.
14. Saravolatz LD, Pawalk J, Johnson LB. In vitro susceptibilities and molecular analysis of vancomycin-intermediate and vancomycin resistant Staphylococcus aureus isolates. Clin Infect Dis 2012; 55:582-6.
15. Belley A, Neesham-Grenon E, Arhin FF, McKay GA, Parr TR Jr, Moeck G. Assessment by time-kill methodology of the synergistic effects of oritavancin in combination with other antimicrobial agents against Staphylococcus aureus. Antimicrob Agents Chemother 2008; 52:3820-2.
16. Lefort A, Saleh-Mghir A, Garry L, et al. Activity of LY333328 combined with gentamicin in vitro and in rabbit experimental endocarditis due to vancomycin-susceptible or-resistant Enterococcus faecalis. Antimicrob Agents Chemother 2000; 44:3017-21.
17. Rubino CM, Van Wart SA, Bhavnani SM, et al. Oritavancin population pharmacokinetics in healthy subjects and patients with complicated skin and skin structure infections or bacteremia. Antimicrob Agents Chemother 2009; 53:4422-8.
18. Ambrose PG, Drusano GL, Craig WA. In vivo activity of oritavancin in animal infection models and rationale for a new dosing regimen in humans. Clin Infect Dis 2012; 54(suppl 3):S220-8.
19. Fetterly GJ, Ong CM, Bhavnani SM, et al. Pharmacokinetics of oritavancin in plasma and skin blister fluid following administration of a 200-milligram dose for 3 days or a single 800-milligram dose. Antimicrob Agents Chemother 2005; 49:148-52.
20. Bhavnani SM, Owen JS, Loutit JS, et al. Pharmacokinetics, safety, and tolerability of ascending single intravenous doses of oritavancin administered to healthy human subjects. Diagn Microbiol Infect Dis 2004; 50:95-102.
21. Belley A, Arhin FF, Sarmiento I, et al. Pharmacodynamics of a simulated single 1,200-milligram dose of oritavancin in an in vitro pharmacokinetic/pharmacodynamic model of methicillin-resistant Staphylococcus aureus infection. Antimicrob Agents Chemother 2013; 57:205-11.
22. Boylan CJ, Campanale K, Iversen PW, et al. Pharmacodynamics of oritavancin (LY333328) in a neutropenic-mouse thigh model of Staphylococcus aureus infection. Antimicrob Agents Chemother 2003; 47: 1700-6.
23. Bhavnani SM, Passarell JA, Owen JS, et al. Pharmacokinetic-pharmacodynamic relationships describing the efficacy of oritavancin in patients with Staphylococcus aureus bacteremia. Antimicrob Agents Chemother 2006; 50:994-1000.
24. Kaatz GW, Seo SM, Aeschilmann JR, et al. Efficacy of LY333328 against experimental methicillin-resistant Staphylococcus aureus endocarditis. Antimicrob Agents Chemother 1998; 42:981-3.
25. Saleh-Mghir A, Lefort A, Petegnief Y, et al. Activity and diffusion of LY333328 in experimental endocarditis due to vancomycin-resistant Enterococcus faecalis. Antimicrob Agents Chemother 1999; 43:115-20.
26. Rupp ME, Fey PD, Longo GM. Effect of LY333328 against vancomycinresistant Enterococcus faecium in a rat central venous catheter-associated infection model. J Antimicrob Chemother 2001; 47:705-7.
27. Gerber J, Smirnov A, Wellmer A, et al. Activity of LY333328 in experimental meningitis caused by a Streptococcus pneumoniae strain susceptible to penicillin. Antimicrob Agents Chemother 2001; 45:2169-72.
28. Cabellos C, Fernandez A, Maiques JM, et al. Experimental study of LY333328 (oritavancin), alone and in combination, in therapy of cephalosporin-resistant pneumococcal meningitis. Antimicrob Agents Chemother 2003; 47:1907-11.
29. Baines SD, O'Connor R, Saxton K, et al. Comparison of oritavancin versus vancomycin as treatments for clindamycin-induced Clostridium difficile PCR ribotype 027 infection in a human gut model. J Antimicrob Chemother 2008; 62:1078-85.
30. Dunbar LM, Milata J, McClure TY, et al. Comparison of the efficacy and the safety of oritavancin front-loaded dosing regimens to daily dosing: an analysis of the SIMPLIFI trial. Antimicrob Agents Chemother 2011; 55:3476-84.
31. Corey GR, Kabler H, Mehra P, et al. SOLO I Investigators. Single-dose oritavancin in the treatment of acute bacterial skin infections. N Engl J Med 2014; 370:2180-90.
32. Corey GR, Good S, Jiang H, et al. SOLO II Investigators. Single-dose oritavancin versus 7-10 days of vancomycin in the treatment of grampositive acute bacterial skin and skin structure infections: the SOLO II noninferiority study. Clin Infect Dis 2015; 60:254-62.
33. Talan AD, Krishnadasan A, Gorwitz RJ, et al. Comparison of Staphylococcus aureus from skin and soft-tissue infections in US emergency department patients, 2004 and 2008. Clin Infect Dis 2011; 53:144-9.
34. Liv C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children: executive summary. Clin Infect Dis 2011; 52:285-92.
35. Tice AD, Rehm SJ. Meeting the challenges of methicillin-resistant Staphylococcus aureus with outpatient parenteral antimicrobial therapy. Clin Infect Dis 2010; 51(suppl 2):S171-5.
36. Tice AD. Oritavancin: a new opportunity for outpatient therapy of serious infections. Clin Infect Dis 2012; 54(suppl 3):S239-43.
37. Marculescu C, Berbari EF, Cantey R, Osman DR. Practical considerations in the use of outpatient antimicrobial therapy for musculoskeletal infections. Mayo Clin Proc 2012; 87:98-105.
38. Drugs for MRSA skin and soft-tissue infections. JAMA 2014; 312:1583-4
39. Chapman ALN, Dixon S, Andrews D, et al. Clinical efficacy and costeffectiveness of outpatient parenteral antibiotic therapy (OPAT): a UK perspective. J Antimicrob Chemother 2009; 64:1316-24.